<DOC>
	<DOC>NCT00821587</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.</brief_summary>
	<brief_title>Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation</brief_title>
	<detailed_description>This is a randomized, single-center controlled study comparing two different immunosuppression regimens (CsA and TAC) in patients with recurrent HCV after LT undergoing antiviral therapy for HCV.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males and females age 18 years and older HCV RNA positive by PCR after liver transplantation Elevated ALT at any time point after liver transplantation Protocol liver biopsy (standard of care) consistent with Stage greater than or equal to 2 of Ishak fibrosis score after liver transplantation Able to provide written informed consent Willing to practice acceptable birth control during the study period. Decompensated Cirrhosis hemoglobin &lt; 12 g/dl WBC &lt; 3,500/cubic mm Platelets &lt; 75,000/cubic mm Human immunodeficiency virus infection Pregnancy Positive HbsAg History of coronary artery disease, history of seizure disorder, poorly controlled autoimmune conditions, thyroid dysfunction, diabetes mellitus, major psychosis, intolerance to previous interferonbased therapy other than anemia or neutropenia History of suicidal ideation or suicidal attempts Creatinine &gt; 2.0 mg/dl Severe nonhepatic illnesses</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hepatitis C Post Liver Transplant</keyword>
</DOC>